Key result
Ticagrelor use after fibrinolytic therapy in STEMI patients showed similar TIMI major bleeding rates to clopidogrel (2.6% vs 1.5%; P=0.6) but significantly higher BARC 3-5 bleeding at 1 month.
Why the study?
Using newer, more potent antiplatelet agents early after thrombolysis in STEMI carries a risk of increasing bleeding complications, prompting an evaluation of the safety and efficacy of ticagrelor compared with clopidogrel.
Does ticagrelor increase bleeding complications or improve efficacy compared to clopidogrel in STEMI patients after fibrinolytic therapy?
Observational (n=142)
Does ticagrelor increase bleeding complications or improve efficacy compared to clopidogrel in STEMI patients after fibrinolytic therapy?
Absolute Event Rate: 2.6% vs 1.5%
p-value: p=0.6
In STEMI patients treated with fibrinolytic therapy, ticagrelor reduces MACE compared to clopidogrel but increases BARC 3-5 bleeding at 1 month.
Ticagrelor associated with higher BARC bleeding post-fibrinolysis in STEMI; should not change practice and leaves optimal P2Y12 selection open.
Background: Thrombolytic therapy in the appropriate window period remains the most commonly used therapy in ST-elevation myocardial infarction patients, despite the advantage of primary percutaneous coronary intervention (PCI) over it. Use of newer more potent antiplatelets agents early after thrombolysis carries the chance of increasing bleeding complications, thus we planned to have a study to assess the safety and efficacy of ticagrelor as compared to clopidogrel in thrombolysed patients. Materials and Methods: This was a prospective observational study in Indian patients. A total of 142 patients were enrolled in the study with 76 in the ticagrelor group and 66 in the clopidogrel group. All patients received thrombolysis as the primary reperfusion strategy. Patients receiving either clopidogrel or ticagrelor after thrombolysis irrespective of the subsequent PCI status were followed up for any bleeding events (primary endpoints) as per thrombolysis in myocardial infarction (TIMI) definition and Bleeding Academic Research Consortium (BARC) definition. Major adverse cardiac events (MACE) including death from cardiovascular causes, myocardial infarction (MI), and stroke were also assessed as markers of efficacy and secondary endpoints. Results: Mean time from thrombolysis to study drug use was 18.9 ± 2.1 h in the ticagrelor group as compared to 14.8 ± 3.3 h in the clopidogrel group ( P > 0.05). For major bleeding events (TIMI major), no statistically significant difference was observed between groups (2.6% in ticagrelor vs. 1.5% in clopidogrel) ( P = 0.6). BARC 3–5 bleeding at 1-month follow-up was significantly higher in the ticagrelor group compared to the clopidogrel group ( P = 0.04). At 1-month follow-up, BARC 1–2 or 3–5 bleeding events in the subjects who underwent PCI were higher in the ticagrelor group than the clopidogrel group ( P = 0.03). Patients in the clopidogrel group have more major adverse cardiac events than the ticagrelor group especially driven by more fatal and nonfatal MI in the clopidogrel group ( P = 0.04). Conclusions: Ticagrelor can be safely administered in postthrombolytic patients similar to clopidogrel albeit at the cost of slightly increased minor bleeding events in short-term follow-up.
No takes yet. Share an insight, caveat, or question.
Vijay et al. (2022) conducted an observational in ST-elevation myocardial infarction (n=142). Ticagrelor vs. Clopidogrel was evaluated on Major bleeding events (TIMI major) (p=0.6). Ticagrelor use after fibrinolytic therapy in STEMI patients showed similar TIMI major bleeding rates to clopidogrel (2.6% vs 1.5%; P=0.6) but significantly higher BARC 3-5 bleeding at 1 month.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: